Vor Biopharma Inc.

VOR

Held by 1 specialist biotech fund

Share on X

Fund Holdings

RA Capital Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13D/ARA Capital Management19.9%Mar 16, 2026

SC 13D/ARA Capital Management14.0%Dec 18, 2025

SC 13D/A

Position Details

RA Capital ManagementNEWFeb 17, 2026

Shares: 5,404,998Value: $70.7M

**Signal Note: RA Capital initiates $70.7M position in Vor Biopharma** RA Capital's entry into VOR likely signals confidence in VOR20019, the company's ex vivo CRISPR-edited CAR-T for acute myeloid leukemia (AML), ahead of anticipated clinical readouts. The $70.7M stake (5.4M shares) represents a material conviction bet on a differentiated cell therapy approach in a high-unmet-need hematologic malignancy where current standard-of-care remains limited.

More VOR Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

SLDB1 fund SION1 fund SPRY1 fund ABOS1 fund TSHA1 fund PCSC1 fund RNA1 fund QGEN

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: